View Older Stories View More Recent Stories

Nov 29, 2016 12:00PM Onxeo Strengthens AsiDNATM Patent Protection in Europe
Nov 28, 2016 12:00PM Onxeo to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference
Nov 21, 2016 12:00PM Onxeo Announces 9th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC
Nov 4, 2016 01:00PM Onxeo Announces Promising Results from Preclinical Studies of Livatag® in Pancreatic Cancer
Oct 27, 2016 12:00PM Onxeo Announces Promising Results from Preclinical Study of Beleodaq® Combination with Checkpoint Inhibitors
Oct 25, 2016 12:00PM Onxeo Reports Third Quarter 2016 Financial Information and Provides Business Update
Oct 10, 2016 12:00PM Onxeo to Present at the 15th Annual BIO Investor Forum in San Francisco
Sep 12, 2016 01:30AM Onxeo Announces First Outcomes of Livatag® Preclinical Plan
Sep 7, 2016 12:30PM Onxeo to Present at the 18th Annual Rodman and Renshaw Global Investment Conference in New York
Sep 7, 2016 12:00PM Onxeo S.A.: Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction
Jul 28, 2016 12:00PM Onxeo Reports First-Half 2016 Business Update and Consolidated Financials
Jul 27, 2016 12:00PM Onxeo Signs Exclusive License Agreement with Pint Pharma for the Commercialization of Beleodaq® in PTCL in South America
Jul 7, 2016 02:00PM Onxeo collaborates with the Royal College of Surgeons in Ireland for research program on Beleodaq® derivatives
Jul 4, 2016 02:00AM Onxeo Receives USPTO Notice of Allowance for Key AsiDNATM Patent, Extending IP Protection in the U.S. until 2031
Jun 27, 2016 12:45PM Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA
Jun 2, 2016 12:31PM Onxeo Announces Development of Beleodaq® Oral Formulation Opening New Opportunities for Its HDAC Inhibitor
May 4, 2016 12:27PM Onxeo S.A.: Publication of 2015 Reference Document
May 2, 2016 12:00PM Onxeo First Quarter 2016 Financial information and Business Update
Apr 28, 2016 12:31PM Onxeo First Quarter 2016 Financial information and Business Update
Apr 18, 2016 02:00PM Onxeo Final Data from Mechanistic Livatag® Study Show Preferential Affinity for Liver, Support Use as Advanced HCC Treatment
Apr 6, 2016 12:00PM Passing on Onxeo’s Extraordinary and Ordinary General Meeting
Apr 4, 2016 12:00PM Onxeo announces positive DSMB recommendation to continue Livatag® ReLive study in HCC
Mar 25, 2016 01:00PM Onxeo Announces Closing of DNA Therapeutics Acquisition
Mar 21, 2016 03:00AM Onxeo Announces Establishment of U.S. Subsidiary
Mar 16, 2016 05:30PM Onxeo Poster Demonstrating Unique Livatag® Mechanism of Action Accepted for Presentation at AACR Annual Meeting
Feb 29, 2016 12:40PM Onxeo Announces Acquisition of DNA Therapeutics and Provides Update on Validive® Development Plan
Feb 26, 2016 11:45AM Onxeo Reports 2015 Full-Year Results and Provides Business Update
Feb 22, 2016 12:15PM Onxeo Expands Collaborations to Advance Development Program of Key Orphan Oncology Assets in Combination with Immuno-Oncology Agents
Feb 17, 2016 12:00PM Onxeo to Attend Upcoming Investor Conferences and Medical Meetings
Jan 25, 2016 12:00PM Onxeo Announces the Evolution and Reinforcement of Its Board of Directors
Dec 17, 2015 12:52PM Onxeo S.A.: Publication of Shareholders Letter
Dec 15, 2015 12:00PM Onxeo announces its financial calendar for 2016
Nov 5, 2015 02:00PM Onxeo Reports Third Quarter 2015 Business Update
Oct 6, 2015 01:04PM Onxeo Announces Evolution in the Board of Directors
Sep 30, 2015 12:00PM Onxeo S.A.: Publication of a New Letter to Shareholders
Sep 17, 2015 02:30AM Corporate Governance prize awarded by AGEFI: Onxeo receives “Silver Governance” for the second consecutive year
Sep 15, 2015 12:00PM Onxeo Files Application for Key Livatag® Patent
Sep 8, 2015 12:00PM Onxeo to present at InvestorDagen 2015
Sep 3, 2015 12:15PM Onxeo S.A.: Publication of a Shareholders Letter
Aug 31, 2015 12:41PM Capital Increase in Onxeo Resulting from the Exercise of Share Subscription Options from Employees
Jul 30, 2015 01:07PM Onxeo Reports First Half 2015 Business Update and Consolidated Accounts
Jul 21, 2015 12:34PM Onxeo: Update on ReLive, Livatag® International Phase III Clinical Trial in HCC
Jun 18, 2015 12:45PM Onxeo Consolidates Its Industrial Property with a US Patent Protecting Validive® until 2029
Jun 3, 2015 12:00PM Onxeo Meets US Investors During “French Life Sciences Days” Event in New York on June 17 & 18, 2015
May 28, 2015 12:01PM Onxeo Announces Preclinical & Clinical Data from Three Studies Supporting the Potential For Belinostat in Multiple Orphan Oncology Indications
May 26, 2015 12:00PM Onxeo Announces Final Data from Completed Phase II Trial of Validive® for the Prevention of Severe Oral Mucositis in Head and Neck Cancer Patients
May 20, 2015 12:00PM Onxeo’s Combined General Meeting of Shareholders
View More Recent Stories View Older Stories